Controversies in treatment of AML: case-based discussion.
Treatment of acute myeloid leukemia (AML) in older adults remains a tremendous challenge. Standard approaches to treatment have resulted in progression-free survival in only a small minority of patients with AML over the age of 60. Elucidation of the molecular genetic events that contribute to the pathogenesis of AML in older patients are providing insights into mechanisms of resistance. This knowledge is also providing new opportunities to begin to refine and direct novel therapies for these heterogeneous diseases. In this case-based review, prognostic factors for treatment outcome in older adults will be covered along with discussion of a risk-based approach to potential therapeutic options, ranging from palliative care to novel therapies and reduced-intensity allogenic transplant.
Stock
Wendy
W
University of Chicago, Section Hem./Onc., 5841 S Maryland, M/C 2115, Chicago IL 60637, USA. wstock@medicine.bsd.uchicago.edu
D000208:Acute Disease; D000368:Aged; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D010166:Palliative Care; D018570:Risk Assessment; D016896:Treatment Outcome